148 related articles for article (PubMed ID: 34783525)
1. Bacteria-Based Live Vehicle for
Jiang T; Yang X; Li G; Zhao X; Sun T; Müller R; Wang H; Li M; Zhang Y
Anal Chem; 2021 Nov; 93(47):15687-15695. PubMed ID: 34783525
[TBL] [Abstract][Full Text] [Related]
2. Fusion expression of bifunctional enzyme complex for luciferin-recycling to enhance the luminescence imaging.
Sun X; Tang X; Wang Q; Chen P; Hill P; Fang B; Xu C
J Photochem Photobiol B; 2018 Aug; 185():66-72. PubMed ID: 29870960
[TBL] [Abstract][Full Text] [Related]
3. Biosynthetic bifunctional enzyme complex with high-efficiency luciferin-recycling to enhance the bioluminescence imaging.
Sun X; Tang X; Hu R; Luo M; Hill P; Fang B; Xu C
Int J Biol Macromol; 2019 Jun; 130():705-714. PubMed ID: 30849466
[TBL] [Abstract][Full Text] [Related]
4. Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging.
Brader P; Stritzker J; Riedl CC; Zanzonico P; Cai S; Burnazi EM; Ghani ER; Hricak H; Szalay AA; Fong Y; Blasberg R
Clin Cancer Res; 2008 Apr; 14(8):2295-302. PubMed ID: 18369089
[TBL] [Abstract][Full Text] [Related]
5. In vivo bioluminescence imaging for the study of intestinal colonization by Escherichia coli in mice.
Foucault ML; Thomas L; Goussard S; Branchini BR; Grillot-Courvalin C
Appl Environ Microbiol; 2010 Jan; 76(1):264-74. PubMed ID: 19880653
[TBL] [Abstract][Full Text] [Related]
6. Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo.
Schultz M; Watzl S; Oelschlaeger TA; Rath HC; Göttl C; Lehn N; Schölmerich J; Linde HJ
J Microbiol Methods; 2005 Jun; 61(3):389-98. PubMed ID: 15767015
[TBL] [Abstract][Full Text] [Related]
7. Development of a Novel ATP Bioluminescence Assay Based on Engineered Probiotic
Park JS; Kim YW; Kim H; Kim SK; Park K
J Microbiol Biotechnol; 2023 Nov; 33(11):1506-1512. PubMed ID: 37482802
[TBL] [Abstract][Full Text] [Related]
8. Role of F1C fimbriae, flagella, and secreted bacterial components in the inhibitory effect of probiotic Escherichia coli Nissle 1917 on atypical enteropathogenic E. coli infection.
Kleta S; Nordhoff M; Tedin K; Wieler LH; Kolenda R; Oswald S; Oelschlaeger TA; Bleiss W; Schierack P
Infect Immun; 2014 May; 82(5):1801-12. PubMed ID: 24549324
[TBL] [Abstract][Full Text] [Related]
9. Probiotic Escherichia coli Nissle 1917 propelled micro-robot with pH sensitivity for hypoxia targeted intestinal tumor therapy.
Wang T; Yin Q; Huang HY; Wang Z; Song H; Luo X
Colloids Surf B Biointerfaces; 2023 May; 225():113277. PubMed ID: 36996630
[TBL] [Abstract][Full Text] [Related]
10. Intestinal probiotics
He L; Yang H; Tang J; Liu Z; Chen Y; Lu B; He H; Tang S; Sun Y; Liu F; Ding X; Zhang Y; Hu S; Xia L
J Biol Eng; 2019; 13():58. PubMed ID: 31297149
[TBL] [Abstract][Full Text] [Related]
11. Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy.
Li R; Helbig L; Fu J; Bian X; Herrmann J; Baumann M; Stewart AF; Müller R; Li A; Zips D; Zhang Y
Res Microbiol; 2019 Mar; 170(2):74-79. PubMed ID: 30447257
[TBL] [Abstract][Full Text] [Related]
12. Antagonistic effects of probiotic Escherichia coli Nissle 1917 on EHEC strains of serotype O104:H4 and O157:H7.
Rund SA; Rohde H; Sonnenborn U; Oelschlaeger TA
Int J Med Microbiol; 2013 Jan; 303(1):1-8. PubMed ID: 23312798
[TBL] [Abstract][Full Text] [Related]
13. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity.
Ukena SN; Singh A; Dringenberg U; Engelhardt R; Seidler U; Hansen W; Bleich A; Bruder D; Franzke A; Rogler G; Suerbaum S; Buer J; Gunzer F; Westendorf AM
PLoS One; 2007 Dec; 2(12):e1308. PubMed ID: 18074031
[TBL] [Abstract][Full Text] [Related]
14. Probiotic Escherichia coli Nissle 1917-derived outer membrane vesicles enhance immunomodulation and antimicrobial activity in RAW264.7 macrophages.
Hu R; Lin H; Li J; Zhao Y; Wang M; Sun X; Min Y; Gao Y; Yang M
BMC Microbiol; 2020 Aug; 20(1):268. PubMed ID: 32854612
[TBL] [Abstract][Full Text] [Related]
15. Prospective and challenges of live bacterial therapeutics from a superhero
Effendi SSW; Ng IS
Crit Rev Microbiol; 2023 Sep; 49(5):611-627. PubMed ID: 35947523
[No Abstract] [Full Text] [Related]
16. Monitoring of bactericidal action of laser by in vivo imaging of bioluminescent E. coli in a cutaneous wound infection.
Jawhara S; Mordon S
Lasers Med Sci; 2006 Sep; 21(3):153-9. PubMed ID: 16897111
[TBL] [Abstract][Full Text] [Related]
17. Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis.
Yan X; Liu XY; Zhang D; Zhang YD; Li ZH; Liu X; Wu F; Chen GQ
Cell Mol Immunol; 2021 Oct; 18(10):2344-2357. PubMed ID: 34480146
[TBL] [Abstract][Full Text] [Related]
18. Uptake kinetics and biodistribution of 14C-D-luciferin--a radiolabeled substrate for the firefly luciferase catalyzed bioluminescence reaction: impact on bioluminescence based reporter gene imaging.
Berger F; Paulmurugan R; Bhaumik S; Gambhir SS
Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2275-85. PubMed ID: 18661130
[TBL] [Abstract][Full Text] [Related]
19. Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats.
Matuskova Z; Anzenbacherova E; Vecera R; Tlaskalova-Hogenova H; Kolar M; Anzenbacher P
PLoS One; 2014; 9(2):e87150. PubMed ID: 24505278
[TBL] [Abstract][Full Text] [Related]
20. Probiotic
Zhao Z; Xu S; Zhang W; Wu D; Yang G
Food Funct; 2022 Jun; 13(11):5914-5924. PubMed ID: 35583304
[No Abstract] [Full Text] [Related]
[Next] [New Search]
